Beroni Group’s Enhanced COVID-19 Antigen Rapid Test Kit Received CE Certification
June 01, 2022 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, June 01, 2022 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, announced that it has received notification...
Beroni Group Announces Appointment of Dr. John Chiplin to Board of Directors
March 31, 2022 08:25 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, March 31, 2022 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise...
Beroni Group to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th from 9:00 a.m. - 5:00 p.m. EDT
March 23, 2022 14:00 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, March 23, 2022 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise...
Beroni Group Sets Up a New R&D Centre in High-Tech Hub in Zhuhai, China
January 31, 2022 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise...
Beroni Group Received a US$1.07 Million Order for COVID-19 Antigen Test Kits from Japan
November 18, 2021 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise...
Beroni Group Published an Article Related to Single-Domain Antibodies in the FEBS Journal
October 28, 2021 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based biopharmaceutical enterprise, today announced...
Beroni Group Received Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAO
September 09, 2021 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, today announced that PENAO Pty...
Beroni Group Announced the Latest Clinical Study of its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method)
August 31, 2021 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, announced the latest clinical...
Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO
August 18, 2021 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise, announced that PENAO...
Beroni Group Signs MoU with tella, Inc to Collaborate in Immunotherapy for Cancer Treatment
May 28, 2021 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, May 28, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise today...